Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA publishes list of drugs undergoing safety scrutiny

This article was originally published in Scrip

Executive Summary

The US FDAhas embarked on a new method for disclosing when marketed drugs are undergoing heightened safety scrutiny by the agency. However, the initiative has raised questions about the scarcity of information released, the potential impact on patient use of medicines, and negative ramifications for product sponsors.

You may also be interested in...



Informed Consent: For COVID-Affected Studies, A Handwritten Document May Suffice

Under certain circumstances, potential clinical trial participants may be able to provide informed consent by writing on a blank piece of paper that they voluntarily agree to participate in a given protocol and texting or emailing a photo of the signed document to the investigator, US FDA says in latest guidance update.

US FDA, Industry Share Early Lessons From Complex Innovative Trial Designs Program

Timelines in the CID program are tight, and sponsors should have a ‘fully baked’ trial design before heading into their first meeting with the agency, industry reps say; agency needs more simulation data from participating sponsors earlier and is working to ensure continuity for firms after the second of two meetings allowed under the program.

US FDA Will Leverage Current Clinical Trial Data In Deciding On Post-COVID Flexibilities

Oncology Center of Excellence’s Paul Kluetz says agency intends to explore the effects of decentralization, remote assessments and other approaches adopted mid-stream on safety evaluations, missing data and endpoint variability.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1132940

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel